magnesium;trifluoromethanesulfonate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: magnesium;trifluoromethanesulfonate
• 化学式: C2F6MgO6S2
• 分子量: 322.4
• InChiKey: BZQRBEVTLZHKEA-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -0.28
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  131
• 氢给体数：
  0
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  6-(3Chlorophenyl)-4-cyclopropyl-1-(4-methoxybenzyl)-1H-quinazolin-2-one 、 magnesium;trifluoromethanesulfonate 、 甲基溴化镁 在 氮气 、 氯化铵 、 盐酸 、 乙酸乙酯 、 Brine 、 magnesium sulfate 、 三氟乙酸 、 ice water 、 水 、 二氯甲烷 、 甲醇 、 silica gel 作用下， 以 乙醚 为溶剂， 反应 75.83h， 以to give 6-(3-chlorophenyl)-4-cyclopropyl-4-methyl-3,4-dihydro-1H-quinazolin-2-one as off-white solid (40 mg, 43%)的产率得到6-(3-chlorophenyl)-4-cyclopropyl-4-methyl-3,4-dihydro-1H-quinazolin-2-one
  参考文献：
  名称：

  Quinazolinone and benzoxazine derivatives as progesterone receptor modulators

  摘要：

  本发明提供了具有下列一般结构的孕激素受体激动剂和拮抗剂化合物：其中：R1和R2独立地选自H、CORA、或NRBCORA，或可选择取代的烷基、烯基、炔基、环烷基、芳香基或杂环基；或R1和R2融合形成3到8个成员的螺环烷基、烯基或杂环环；RA为H或可选择取代的烷基、芳香基、烷氧基或氨基烷基；RB为H、C1至C3烷基或取代的C1至C3烷基；R3为H、OH、NH2、CORC或可选择取代的烷基、烯基或炔基；RC为H或可选择取代的烷基、芳香基、烷氧基或氨基烷基；R4为H、卤素、CN、NO2或可选择取代的烷基、炔基、烷氧基、氨基或氨基烷基；R5为可选择取代的苯或具有1、2或3个来自O、S、SO、SO2或NR6的杂原子的五元或六元环；R6为H或C1至C3烷基；G1为O、NR7或CR7R8；G2为CO、CS或CR7R8；但当G1为O时，G2为CR7R8，且G1和G2不能同时为CR7R8；R7和R8为H或可选择取代的烷基、芳香基或杂环基；或其药学上可接受的盐，并且使用这些化合物作为孕激素受体的激动剂或拮抗剂在哺乳动物中进行方法。

  公开号：

  US06358948B1

文献信息

• Novel benzosultam oxazolidinone antibacterial agents
  申请人：——

  公开号：US20010047018A1

  公开（公告）日：2001-11-29

  The present invention provides a compound of formula I 1 which have potent antibacterial activities.

  本发明提供了一种具有强效抗菌活性的化合物，其化学式为I1。
• Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
  申请人：——

  公开号：US20020094983A1

  公开（公告）日：2002-07-18

  This invention provides compounds which are agonists and antagonists of the progesterone receptor having the general structure: 1 wherein: R 1 and R 2 are independently selected from H, COR A , or NR B COR A , or optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heterocyclic moieties; or R 1 and R 2 are fused to form: 3 to 8 membered spirocyclic alkyl, alkenyl or heterocyclic rings; R A is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl groups; R B is H, C 1 to C 3 alkyl, or substituted C 1 to C 3 alkyl; R 3 is H, OH, NH 2 , COR C or optionally substituted alkyl, alkenyl, or alkynyl; R C is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; R 4 is H, halogen, CN, NO 2 , or optionally substituted alkyl alkynyl, alkoxy, amino or aminoalkyl; R 5 is an optionally substituted benzene or five or six membered ring with 1, 2, or 3 heteroatoms selected from O, S, SO, SO 2 or NR 6 ; R 6 is H or C 1 to C 3 alkyl; G 1 is O, NR 7 , or CR 7 R 8 ; G 2 is CO, CS, or CR 7 R 8 ; provided that when G 1 is O, G 2 is CR 7 R 8 , and G 1 and G 2 cannot both be CR 7 R 8 ; R 7 and R 8 are H or an optionally substituted alkyl, aryl, or heterocyclic moiety; or pharmaceutically acceptable salt thereof, and methods using these compounds in mammals as agonists or antagonists of the progesterone receptor.

  本发明提供了具有以下一般结构的孕激素受体激动剂和拮抗剂化合物：1其中：R1和R2独立地选自H、CORA、或NRBCORA，或可选择取代的烷基、烯基、炔基、环烷基、芳基或杂环基；或者R1和R2融合形成3至8成员的螺环烷基、烯基或杂环环；RA为H或可选择取代的烷基、芳基、烷氧基或氨基烷基；RB为H、C1至C3烷基或取代的C1至C3烷基；R3为H、OH、NH2、CORA或可选择取代的烷基、烯基或炔基；RC为H或可选择取代的烷基、芳基、烷氧基或氨基烷基；R4为H、卤素、CN、NO2或可选择取代的烷基、炔基、烷氧基、氨基或氨基烷基；R5为可选择取代的苯环或带有1、2或3个杂原子（选自O、S、SO、SO2或NR6）的五元或六元环；R6为H或C1至C3烷基；G1为O、NR7或CR7R8；G2为CO、CS或CR7R8；前提是当G1为O时，G2为CR7R8，且G1和G2不能同时为CR7R8；R7和R8为H或可选择取代的烷基、芳基或杂环基；或其药学上可接受的盐，以及在哺乳动物中使用这些化合物作为孕激素受体激动剂或拮抗剂的方法。
• Substituted oxetanes, method of making, and method of use thereof
  申请人：Howell R. Amy

  公开号：US20050215568A1

  公开（公告）日：2005-09-29

  Oxetane-containing nucleosides, particularly non-reducing psiconucleoside oxetanes are described herein. Therapeutic application of these oxetane compounds toward the treatment of nucleoside analog related disorders such as disorders involving cellular proliferation and infection are also described.

  本文描述了含有氧杂环丙烷的核苷类化合物，特别是非还原型偏心核苷类氧杂环丙烷。还描述了这些氧杂环丙烷化合物在治疗与核苷类似物相关的疾病，例如涉及细胞增殖和感染的疾病方面的治疗应用。
• Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands
  申请人：Fukumoto Shoji

  公开号：US20090253687A1

  公开（公告）日：2009-10-08

  The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineral corticoidreceptorantagonistic action and is useful as an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like, a compound having a fused heterocycle, or a prodrug thereof, or a salt thereof; and an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like.

  本发明涉及其中每个符号如规范所定义的化合物，该化合物具有优越的矿物质皮质激素受体拮抗作用，可作为预防或治疗高血压、心力衰竭等药物，包括具有融合杂环的化合物、其前药或其盐；以及预防或治疗高血压、心力衰竭等疾病的药剂。
• Cyclic regimens using quinazolinone and benzoxazine derivatives
  申请人：Wyeth

  公开号：US06498154B1

  公开（公告）日：2002-12-24

  This invention relates to cyclic combination therapies utilizing, in combination with progestins, estrogens, or both, compounds which are progesterone receptor antagonists of the general structure: wherein: R1 and R2 are H, CORA, or NRBCORA, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heterocyclic; or R1 and R2 fuse to form 3 to 8 membered spirocyclic alkyl, alkenyl or heterocyclic rings; RA is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl groups; RB is H or alkyl; R3 is H, OH, NH2, CORC or alkyl, alkenyl, or alkynyl; RC is H, alkyl, aryl, alkoxy, or aminoalkyl; R4 is H, halogen, CN, NO2, alkyl, alkynyl, alkoxy, amino or aminoalkyl; R5 is benzene or 5- or 6-membered heterocyclic ring; R6 is H or alkyl; G1 is O, NR7, or CR7R8; G2 is CO or CR7R8; provided that when G1 is O, G2 is CR7R8, and G1 and G2 cannot both be CR7R8; R7 and R8 are H or an optionally substituted alkyl, aryl, or heterocyclic moiety; or pharmaceutically acceptable salt thereof. These methods may be used for contraception or treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minimization of side effects or cyclic menstrual bleeding. Additional uses of the invention include stimulation of food intake.

  本发明涉及循环联合疗法，利用孕激素受体拮抗剂与孕激素、雌激素或两者的结合物相结合，其一般结构为：其中：R1和R2为H、CORA或NRBCORA、烷基、烯基、炔基、环烷基、芳基或杂环基；或R1和R2融合形成3至8个成员的螺环烷基、烯基或杂环环；RA为H或可选取代的烷基、芳基、烷氧基或氨基烷基；RB为H或烷基；R3为H、OH、NH2、CORC或烷基、烯基或炔基；RC为H、烷基、芳基、烷氧基或氨基烷基；R4为H、卤素、CN、NO2、烷基、炔基、烷氧基、氨基或氨基烷基；R5为苯环或5-或6-成员杂环环；R6为H或烷基；G1为O、NR7或CR7R8；G2为CO或CR7R8；前提是当G1为O时，G2为CR7R8，且G1和G2不能同时为CR7R8；R7和R8为H或可选取代的烷基、芳基或杂环基；或其药学上可接受的盐。这些方法可用于避孕或治疗和/或预防继发性闭经、功能性出血、子宫平滑肌瘤、子宫内膜异位症、多囊卵巢综合症、子宫内膜癌、卵巢癌、乳腺癌、结肠癌、前列腺癌或最小化副作用或周期性月经出血。本发明的其他用途包括促进食物摄入。